Johnson Fistel, PLLP is investigating TransMedics Group, Inc. following the company's Q1 2026 financial report that showed declining operating margins and increased expenses due to investments in growth and supply chain costs. Despite revenue growth, TransMedics warned adjusted operating margins would remain below 2025 levels, causing a sharp stock price drop. The investigation aims to determine if TransMedics complied with federal securities laws and if investors who suffered losses can recover them.
TransMedics reported a Q2 earnings beat mainly due to gains in low-margin logistics and pricing rather than increased organ transplants on its platform. Revenue growth was concentrated in liver transplants, which make up 78% of organ revenue, while h...
Rosen Law Firm has announced an investigation into potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. This move could impact shareholders as it suggests possible mismanagement or misconduct at the company....
TransMedics Group reported a 21% increase in total revenue to $189.9 million for Q2 2026, driven by higher usage of its Organ Care System and logistics services. Despite a net income decline to $14.7 million due to increased operating expenses from s...
TransMedics Group, a medical tech company specializing in organ transplant therapy, granted 18,762 stock options and 12,414 restricted stock units to 9 new employees on July 29, 2026. These grants serve as inducements for employment and were approved...
